Destiny Pharma, a UK-based biotech firm, specializes in infection prevention with late-stage assets targeting Clostridium difficile and post-surgical Staphylococcus aureus infections. The company focuses on advancing therapeutic solutions in infectious disease management, establishing itself as a specialized entity in the biotech sector dedicated to combating serious bacterial infections.

‌